# Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

Source: https://onco.cc/trials/nct04196465/  
OnCo record `nct04196465` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IMC-001 run by Asan Medical Center, active and no longer recruiting.

## Summary

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers is a phase 2 interventional study registered as NCT04196465 by Asan Medical Center, with 48 participants planned, started 2019-09-09. Conditions recorded: Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer and Subjects With Resectable Liver Cancer. Interventions recorded: IMC-001.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04196465
- Phase: 2
- Setting: Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)
- Sponsor: Asan Medical Center
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT04196465: https://clinicaltrials.gov/study/NCT04196465

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [IMC-001](https://onco.cc/drugs/imc-001/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04196465.json